Short Interest in Nicox SA (OTCMKTS:NICXF) Expands By 95,238.1%

Nicox SA (OTCMKTS:NICXF) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 20,021 shares, a growth of 95,238.1% from the January 29th total of 21 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. Currently, 0.0% of the shares of the stock are short sold.

Nicox Price Performance

Shares of NICXF stock remained flat at $0.30 on Wednesday. The business has a 50 day moving average price of $0.30 and a two-hundred day moving average price of $0.30. Nicox has a 1-year low of $0.25 and a 1-year high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.